189 related articles for article (PubMed ID: 35202353)
21. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet.
Cowie RL; Brink BA
S Afr Med J; 1990 Apr; 77(8):390-1. PubMed ID: 2184527
[TBL] [Abstract][Full Text] [Related]
22. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
[TBL] [Abstract][Full Text] [Related]
23. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
[TBL] [Abstract][Full Text] [Related]
25. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
[TBL] [Abstract][Full Text] [Related]
26. [Short-course chemotherapy of tuberculosis with pyrazinamide].
Asai S; Futsuki Y; Tomari S; Araki J
Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
[TBL] [Abstract][Full Text] [Related]
27. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Pettit AC; Phillips PPJ; Kurbatova E; Vernon A; Nahid P; Dawson R; Dooley KE; Sanne I; Waja Z; Mohapi L; Podany AT; Samaneka W; Savic RM; Johnson JL; Muzanyi G; Lalloo UG; Bryant K; Sizemore E; Scott N; Dorman SE; Chaisson RE; Swindells S;
Clin Infect Dis; 2023 Feb; 76(3):e580-e589. PubMed ID: 36041016
[TBL] [Abstract][Full Text] [Related]
28. Failure of a prothionamide-containing oral antituberculosis regimen.
Langton ME; Cowie RL
S Afr Med J; 1985 Dec; 68(12):881. PubMed ID: 4071346
[TBL] [Abstract][Full Text] [Related]
29. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
[TBL] [Abstract][Full Text] [Related]
30. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
Am Rev Respir Dis; 1981 Feb; 123(2):165-70. PubMed ID: 7015933
[TBL] [Abstract][Full Text] [Related]
31. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
[TBL] [Abstract][Full Text] [Related]
32. Improving treatment outcome assessment in a mouse tuberculosis model.
Mourik BC; Svensson RJ; de Knegt GJ; Bax HI; Verbon A; Simonsson USH; de Steenwinkel JEM
Sci Rep; 2018 Apr; 8(1):5714. PubMed ID: 29632372
[TBL] [Abstract][Full Text] [Related]
33. Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
Cowie RL; Langton ME; Escreet BC
S Afr Med J; 1985 Dec; 68(12):879-80. PubMed ID: 4071345
[TBL] [Abstract][Full Text] [Related]
34. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
[TBL] [Abstract][Full Text] [Related]
35. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Wada M
Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
[TBL] [Abstract][Full Text] [Related]
36. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
[No Abstract] [Full Text] [Related]
37. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study.
Tubercle; 1986 Mar; 67(1):5-15. PubMed ID: 3521015
[TBL] [Abstract][Full Text] [Related]
38. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
39. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.
Combs DL; O'Brien RJ; Geiter LJ
Ann Intern Med; 1990 Mar; 112(6):397-406. PubMed ID: 2155569
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
García-Rodríguez JF; Valcarce-Pardeiro N; Álvarez-Díaz H; Mariño-Callejo A
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
